To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).
Armenia, D., Di Carlo, D., Calcagno, A., Vendemiati, G., Forbici, F., Bertoli, A., et al. (2016). Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, dkw512 [10.1093/jac/dkw512].
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen
ARMENIA, DANIELE;BERTOLI, ADA;CARTA, STEFANIA;ANDREONI, MASSIMO;CECCHERINI SILBERSTEIN, FRANCESCA;PERNO, CARLO FEDERICO;Santoro, MM
2016-12-20
Abstract
To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2016_Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV1 infected patients _JAC.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
4.2 MB
Formato
Adobe PDF
|
4.2 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
